CN113490850B - 用于治疗乳腺癌的诊断和治疗方法 - Google Patents
用于治疗乳腺癌的诊断和治疗方法 Download PDFInfo
- Publication number
- CN113490850B CN113490850B CN201980067809.7A CN201980067809A CN113490850B CN 113490850 B CN113490850 B CN 113490850B CN 201980067809 A CN201980067809 A CN 201980067809A CN 113490850 B CN113490850 B CN 113490850B
- Authority
- CN
- China
- Prior art keywords
- score
- breast cancer
- individual
- estrogen receptor
- pathway activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H80/00—ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Medical Informatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Primary Health Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862719545P | 2018-08-17 | 2018-08-17 | |
| US62/719,545 | 2018-08-17 | ||
| PCT/US2019/046814 WO2020037203A2 (en) | 2018-08-17 | 2019-08-16 | Diagnostic and therapeutic methods for the treatment of breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113490850A CN113490850A (zh) | 2021-10-08 |
| CN113490850B true CN113490850B (zh) | 2024-12-06 |
Family
ID=67809706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980067809.7A Active CN113490850B (zh) | 2018-08-17 | 2019-08-16 | 用于治疗乳腺癌的诊断和治疗方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11081236B2 (https=) |
| EP (1) | EP3837548A2 (https=) |
| JP (1) | JP7571006B2 (https=) |
| KR (1) | KR102754524B1 (https=) |
| CN (1) | CN113490850B (https=) |
| AU (1) | AU2019321588B2 (https=) |
| CA (1) | CA3109090A1 (https=) |
| IL (1) | IL280707B2 (https=) |
| MX (1) | MX2021001857A (https=) |
| TW (1) | TW202022124A (https=) |
| WO (1) | WO2020037203A2 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2909576T3 (es) * | 2016-10-11 | 2022-05-09 | Univ Duke | Tratamiento con lasofoxifeno del cáncer de mama ER+ |
| JP7571006B2 (ja) | 2018-08-17 | 2024-10-22 | ジェネンテック， インコーポレイテッド | 乳がんの処置のための診断的および治療的方法 |
| KR20220034129A (ko) | 2019-07-07 | 2022-03-17 | 올레마 파마슈티컬스 인코포레이티드 | 에스트로겐 수용체 길항제 요법 |
| AU2020399168A1 (en) * | 2019-12-09 | 2022-07-28 | Sanofi | Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative |
| CA3169679A1 (en) * | 2020-03-06 | 2021-09-10 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
| CN115551513B (zh) | 2020-05-12 | 2025-05-02 | 基因泰克公司 | 使用包含gdc-9545和cdk4/6抑制剂的组合疗法治疗乳腺癌 |
| CN111893112A (zh) * | 2020-08-12 | 2020-11-06 | 上海尤里卡信息科技有限公司 | 胃癌肿瘤标志物及其应用 |
| CN114105977B (zh) * | 2020-08-28 | 2023-09-01 | 先声再明医药有限公司 | 雌激素受体调节剂化合物及其用途 |
| EP4247977A2 (en) * | 2020-11-23 | 2023-09-27 | Sanofi | Panel of er regulated genes for use in monitoring endocrine therapy in breast cancer |
| EP4267578A4 (en) | 2020-12-23 | 2024-11-20 | Recurium IP Holdings, LLC | ESTROGEN RECEPTOR MODULATORS |
| WO2022166983A1 (zh) * | 2021-02-08 | 2022-08-11 | 贝达药业股份有限公司 | 杂芳基并哌啶类衍生物及其药物组合物和应用 |
| TWI808648B (zh) * | 2021-02-16 | 2023-07-11 | 美商建南德克公司 | 使用包含gdc-9545及gdc-0077之組合療法治療乳癌 |
| AU2022222660A1 (en) | 2021-02-16 | 2023-07-27 | Genentech, Inc. | Treatment of breast cancer using combination therapies comprising gdc-9545 and abemaciclib or ribociclib |
| JP2024506347A (ja) | 2021-02-16 | 2024-02-13 | ジェネンテック， インコーポレイテッド | Ｇｄｃ－９５４５およびイパタセルチブを含む併用療法を使用する乳がんの処置 |
| AU2022291768A1 (en) | 2021-06-16 | 2023-11-30 | Celgene Corporation | Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases |
| TW202317539A (zh) * | 2021-07-15 | 2023-05-01 | 大陸商四川海思科製藥有限公司 | 芳氨基衍生物雌激素受體調節劑及其用途 |
| US20240339201A1 (en) * | 2021-08-09 | 2024-10-10 | Korea University Research And Business Foundation | Breast cancer-related information providing method using magnetic resonance image and rna genetic information |
| GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
| WO2023091550A1 (en) * | 2021-11-18 | 2023-05-25 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
| US20250263390A1 (en) * | 2022-04-15 | 2025-08-21 | Sanofi | Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof |
| WO2023221122A1 (en) * | 2022-05-20 | 2023-11-23 | Olema Pharmaceuticals, Inc. | Salts and solid forms of an estrogen receptor antagonist |
| WO2023221123A1 (en) * | 2022-05-20 | 2023-11-23 | Olema Pharmaceuticals, Inc. | Crystalline forms of an estrogen receptor antagonist |
| WO2024015506A1 (en) * | 2022-07-14 | 2024-01-18 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-mediated disorders |
| JP2025533900A (ja) * | 2022-10-05 | 2025-10-09 | オレマ ファーマシューティカルズ， インコーポレイテッド | エストロゲン受容体媒介性障害を治療する方法 |
| WO2024076633A1 (en) * | 2022-10-05 | 2024-04-11 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-mediated disorders |
| WO2025096907A1 (en) * | 2023-11-01 | 2025-05-08 | The Children's Medical Center Corporation | Methods and compositions for immunosuppressant resistant cellular therapies |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5322770A (en) | 1989-12-22 | 1994-06-21 | Hoffman-Laroche Inc. | Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription |
| US6638727B1 (en) * | 1999-01-26 | 2003-10-28 | Cytyc Health Corporation | Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer |
| WO2002092854A2 (en) * | 2001-05-16 | 2002-11-21 | Novartis Ag | Genes expressed in breast cancer as prognostic and therapeutic targets |
| CA2512000C (en) | 2002-12-26 | 2011-08-09 | Eisai Co., Ltd. | Selective estrogen receptor modulator |
| CA2539107A1 (en) | 2003-09-19 | 2005-03-31 | Arcturus Bioscience, Inc. | Predicting breast cancer treatment outcome |
| JP2010538609A (ja) * | 2007-09-06 | 2010-12-16 | バイオセラノスティクス，インコーポレイティド | 腫瘍グレード分類と癌の予後診断 |
| RS56042B1 (sr) | 2010-06-10 | 2017-09-29 | Seragon Pharmaceuticals Inc | Modulatori estrogenih receptora i njihove upotrebe |
| GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| US9499538B2 (en) | 2012-03-20 | 2016-11-22 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| US9169207B2 (en) * | 2012-03-27 | 2015-10-27 | Incuron, Llc | Curaxins for use in treating carcinogen-induced cancer |
| ES2696202T3 (es) | 2012-08-23 | 2019-01-14 | Univ Colorado Regents | Método para determinar el tratamiento de cáncer de mama |
| ES2774935T3 (es) | 2012-10-24 | 2020-07-23 | Univ Illinois | Composiciones y métodos para tratar trastornos médicos relacionados con estrógeno |
| EP2912033A4 (en) | 2012-10-24 | 2016-09-14 | Univ Illinois | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-MEDIATED ILLNESSES |
| EP2938745B1 (en) * | 2012-12-26 | 2020-10-07 | Koninklijke Philips N.V. | Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions |
| MX2015011132A (es) | 2013-03-14 | 2015-11-30 | Seragon Pharmaceuticals Inc | Moduladores policiclicos del receptor de estrogenos y sus usos. |
| BR112016005225B1 (pt) | 2013-09-11 | 2023-11-14 | Bio Theranostics, Inc | Métodos para avaliar câncer de mama em um indivíduo |
| ES3055185T3 (en) | 2014-03-28 | 2026-02-10 | Univ Duke | Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator |
| BR112017007962A2 (pt) * | 2014-10-24 | 2018-01-23 | Koninklijke Philips Nv | método implementado por computador, aparelho, mídia de armazenamento, programa de computador, kit, e, uso do kit |
| TWI874834B (zh) | 2014-12-18 | 2025-03-01 | 瑞士商赫孚孟拉羅股份公司 | 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途 |
| HK1258851A1 (zh) | 2015-11-09 | 2019-11-22 | 豪夫迈‧罗氏有限公司 | 四氢萘雌激素受体调节剂及其用途 |
| KR102479822B1 (ko) | 2016-02-05 | 2022-12-21 | 인벤티스바이오 엘엘씨 | 선택적 에스트로겐 수용체 분해제 및 이들의 용도 |
| EA034994B1 (ru) | 2016-02-15 | 2020-04-15 | Санофи | 6,7-дигидро-5h-бензо[7]аннуленовые производные в качестве модуляторов эстрогеновых рецепторов |
| KR102111792B1 (ko) | 2016-03-25 | 2020-05-18 | 뤄신 바이오테크놀러지 (상하이) 컴퍼니 리미티드 | 에스트로겐 수용체 하향 조절제로서의 치환된 인돌 화합물 |
| CN109843882A (zh) | 2016-06-16 | 2019-06-04 | 豪夫迈·罗氏有限公司 | 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途 |
| EP3472162B1 (en) | 2016-06-16 | 2021-11-17 | F. Hoffmann-La Roche AG | Heteroaryl estrogen receptor modulators and uses thereof |
| US10149839B2 (en) | 2016-07-25 | 2018-12-11 | Astrazeneca Ab | Chemical compounds |
| EP3640251B1 (en) | 2016-10-24 | 2021-12-08 | Astrazeneca AB | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
| WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
| CN110139863B (zh) | 2016-10-28 | 2022-02-18 | 罗欣健康科技发展(北京)有限公司 | 作为雌激素受体降解剂的吲哚并取代哌啶类化合物 |
| ES3039455T3 (en) | 2016-11-17 | 2025-10-21 | Sanofi Sa | Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof |
| MX2019008158A (es) | 2017-01-06 | 2019-12-09 | G1 Therapeutics Inc | Terapia de combinacion para el tratamiento del cancer. |
| JP7571006B2 (ja) | 2018-08-17 | 2024-10-22 | ジェネンテック， インコーポレイテッド | 乳がんの処置のための診断的および治療的方法 |
-
2019
- 2019-08-16 JP JP2021507927A patent/JP7571006B2/ja active Active
- 2019-08-16 CN CN201980067809.7A patent/CN113490850B/zh active Active
- 2019-08-16 CA CA3109090A patent/CA3109090A1/en active Pending
- 2019-08-16 IL IL280707A patent/IL280707B2/en unknown
- 2019-08-16 AU AU2019321588A patent/AU2019321588B2/en active Active
- 2019-08-16 TW TW108129347A patent/TW202022124A/zh unknown
- 2019-08-16 KR KR1020217007867A patent/KR102754524B1/ko active Active
- 2019-08-16 US US16/542,817 patent/US11081236B2/en active Active
- 2019-08-16 WO PCT/US2019/046814 patent/WO2020037203A2/en not_active Ceased
- 2019-08-16 MX MX2021001857A patent/MX2021001857A/es unknown
- 2019-08-16 EP EP19762044.6A patent/EP3837548A2/en active Pending
-
2021
- 2021-06-25 US US17/359,186 patent/US11676731B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL280707A (en) | 2021-03-25 |
| CA3109090A1 (en) | 2020-02-20 |
| WO2020037203A2 (en) | 2020-02-20 |
| US20220044819A1 (en) | 2022-02-10 |
| EP3837548A2 (en) | 2021-06-23 |
| AU2019321588B2 (en) | 2026-02-12 |
| IL280707B2 (en) | 2026-03-01 |
| JP2021533787A (ja) | 2021-12-09 |
| US11081236B2 (en) | 2021-08-03 |
| IL280707B1 (en) | 2025-11-01 |
| KR102754524B1 (ko) | 2025-01-13 |
| US11676731B2 (en) | 2023-06-13 |
| CN113490850A (zh) | 2021-10-08 |
| KR20210046031A (ko) | 2021-04-27 |
| WO2020037203A3 (en) | 2020-03-26 |
| AU2019321588A1 (en) | 2021-03-04 |
| US20200082944A1 (en) | 2020-03-12 |
| TW202022124A (zh) | 2020-06-16 |
| JP7571006B2 (ja) | 2024-10-22 |
| MX2021001857A (es) | 2021-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113490850B (zh) | 用于治疗乳腺癌的诊断和治疗方法 | |
| AU2020270508B2 (en) | C/EBP alpha short activating RNA compositions and methods of use | |
| AU2020202555B2 (en) | Novel fusion molecules and uses thereof | |
| AU2015334841B2 (en) | Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities | |
| AU2015334842B2 (en) | Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities | |
| US20190300967A1 (en) | Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature | |
| KR102149483B1 (ko) | 예측변수 인자들을 이용하여 동정된 환자 부분 모집단에서 암 치료를 위한 마시티닙의 용도 | |
| CN113383085A (zh) | 用于分析核酸分子的方法和系统 | |
| WO2021183218A1 (en) | Compositions and methods for modulating the interaction between ss18-ssx fusion oncoprotein and nucleosomes | |
| US20200300859A1 (en) | Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy | |
| KR20140072035A (ko) | 상피세포 성장 인자 수용체 유전자에서의 돌연변이 | |
| CN1704478A (zh) | 评估急性髓性白血病患者的方法 | |
| US12478665B2 (en) | Cancer vaccine compositions and methods for using same to prevent and/or treat cancer | |
| US12480163B2 (en) | Compositions and methods for identification assessment, prevention, and treatment of Ewing sarcoma using TP53 dependency biomarkers and modulators | |
| KR20070099564A (ko) | 급성 골수성 백혈병 환자를 평가하는 방법 | |
| KR20190126812A (ko) | 질환 진단용 바이오마커 | |
| KR20220008244A (ko) | 전립선암 환자의 예후 진단 및 치료 전략 결정용 연령 특이적 마커 | |
| HK40057217A (en) | Diagnostic and therapeutic methods for the treatment of breast cancer | |
| HK40057217B (zh) | 用於治疗乳腺癌的诊断和治疗方法 | |
| EP1766051A1 (en) | Methods for identifying risk of breast cancer and treatments thereof | |
| KR20220008245A (ko) | 전립선암 환자의 예후 진단 및 치료 전략 결정용 전이 특이적 마커 | |
| HK40060652A (en) | Methods and systems for analyzing nucleic acid molecules | |
| Class et al. | Patent application title: MARKERS OF MELANOMA AND USES THEREOF Inventors: Luca Sigalotti (Maniago (pn), IT) Michele Maio (Roveredo In Piano (pn), IT) Assignees: CENTRO DI RIFERIMENTO ONCOLOGICO-INSTITUTO NAZIONALE TUMORI-AVIANO AZIENDA OSPEDALIERA UNIVERSITARIA SENESE | |
| HK1084696A (en) | Prognostic for hematological malignancy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20211013 Address after: California, USA Applicant after: GENENTECH, Inc. Address before: Basel, Switzerland Applicant before: F. Hoffman-La Roche AG |
|
| TA01 | Transfer of patent application right | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40057217 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |